Intrexon, a US-based synthetic biology company, has made three additions to its executive team.
Jack Bobo joins the company as Senior Vice President, Chief Communications Officer; Samuel Broder returns as Senior Vice President, Head of Health Sector; while Joel Liffmann joins as Senior Vice President, Finance.
Bobo joins the company from the US Department of State where he has worked for the past 13 years, most recently as Senior Advisor for Food Policy following positions as Senior Advisor for Biotechnology, as well as Chief, Biotechnology and Textile Trade Division. Prior to this, he was an attorney at Crowell & Moring LLP.
Broder has had an extensive career in health and is welcomed back to Intrexon in the role of Head of the Health Sector, succeeding Gregory Frost. Previously, he was Chairman of the Health Sector and Executive Vice President of Scientific and Public Affairs.
Prior to Intrexon, Broder was Executive Vice President and Chief Medical Officer at Celera and Senior Vice President of Research and Development at IVAX Corporation. He was also Director of the National Cancer Institute (NCI) for six years.
Liffmann brings to the company extensive knowledge in building growth businesses through internal development, acquisitions and partnerships. He has more than 30 years of public and private capital market financing experience, 20 years of service on public and private company Boards of Directors and 40 years of experience in the healthcare industry. Most recently, he was Executive Vice President of Corporate Development at Health Grades. Prior to this he was a Senior Advisor to Vestar Capital Partners and a Partner at Oracle Investment Management, where he specialised in private company investing and merchant banking in healthcare, bioscience, and related industries.
